Drug Profile

NT 101

Alternative Names: NT-101

Latest Information Update: 07 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NexThera
Class Eye disorder therapies; Peptides
Mechanism of Action Angiogenesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Wet age-related macular degeneration

Most Recent Events

25 Mar 2025 Phase-I/II clinical trials in Wet age-related macular degeneration in USA (Ophthalmic) (NCT06704009)
25 Nov 2024 NexThera plans a phase I trial for Wet age related macular degeneration in USA (Ophthalmic, drops) in January 2025 (NCT06704009)
19 Jul 2024 Preclinical trials in Wet age-related macular degeneration in South Korea (Ophthalmic) before July 2024 (NexThera pipeline, July 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com